Hauptinhalt
PROvendis presents innovations from North Rhine-Westphalia at BIO-Europe 2025
November 3–5, 2025, Vienna, Austria. As co-exhibitor in the German Pavilion, PROvendis presents the latest research results and technologies from North Rhine-Westphalian universities and university hospitals.
PROvendis GmbH promotes technology transfer and acts as a professional service provider in the entire field of IP management for universities, extra-university research institutions, companies, and start-ups. We provide exclusive access to licensable inventions from approximately 30,000 scientists in the areas of medicine, natural sciences, and engineering.
27 North Rhine-Westphalian universities and PROvendis GmbH form the innovation2business.nrw network. The network for intellectual property (IP) promotes the transfer of knowledge and technology to business and society. The network partners use synergies and jointly develop innovations. The University of Münster is the commissioned university and, together with PROvendis, acts as the network coordinator. The network is funded by the state of North Rhine-Westphalia, with the Ministry of Economic Affairs, Industry, Climate Protection and Energy providing the funding.
Meet us at BIO-Europe!
Our Life Sciences Team consists of experienced innovation managers with expertise in biology, chemistry, medicine, and pharma. They identify suitable partners, negotiate license agreements, and promote long-term research collaborations. All technologies are also offered online. Meet us at booth C114-16.
- Dr. Jürgen Walkenhorst, Manager Patents & Licenses, PROvendis GmbH
Technologies
On behalf of the NRW universities, the PROvendis innovation managers offer these and other technologies for licensing and further development with the researchers:
Innovative ELISA Assays for Non-Invasive Lupus Nephritis Diagnosis
Novel YB-1-2G and Anti YB-1-2G Detection Methods for Improved Patient Care Currently, Lupus Nephritis diagnosis relies on invasive kidney biopsies, as there is no validated biomarker to detect kidney involvement in Systemic lupus erythematosus.
Novel Anti-Tuberculosis Compounds
The resurgence of tuberculosis, caused primarily by Mycobacterium tuberculosis (Mtb), and the appearance of multi‐drug and extensively drug resistant Mtb strains strengthen the need for new drugs with alternative modes of action.
OptoRyR
Light-induced opening of Ryanodine receptors Light-induced opening of the Ryanodine receptor for use as a scalable system in drug screening.
SafeGuard-BR system
A lockable intubation adapter system for safe respiratory tract access against infection and contamination The lockable intubation adapter system allows hygienic, protected performance of intensive-care examinations without releasing infectious aerosol particles or droplets into the ambient atmosphere.
ITIH3 - a biomarker for Myasthenia gravis activity
A novel ELISA-based approach The invention aims at monitoring inter-alpha-trypsin inhibitor heavy chain H3 (ITIH3) in the serum of Myasthenia gravis patients as the first biomarker for the assessment of MG disease activity in clinical routine, e.g. for therapy adjustments. Monitoring can easily be made by quantitative ELISA in routine blood collection.
Parthenolide supports PNS repair
Parthenolide and its derivatives for use in the treatment of axonal damage Peripheral nerve damage is a common cause of considerable functional morbidity, and healthcare expenditure.
Synthetic Cytokine Receptors
Synthetic cytokine receptors to control cellular activity Synthetic cytokine receptors (SyCyRs) enable defined background-free cellular responses through addition of synthetic ligands. The system allows the engineering of highly specific amplification or eradication switches for recombinant cells.
GSDMD VHHs prevent pyroptosis
Single domain antibodies (sdAbs) against GSDMD prevent pyroptosis Single domain antibodies (sdAbs) against GSDMD prevent pyroptosis, GSDMD pore formation and IL-1β release. sdAbs act intra and extracellularly.
Treatment of ocular hypertension
Dual Targeting in a New Class of Anti-Glaucoma Agents Increased intraocular pressure (IOP), also known as ocular hypertension, is widely associated with open-angle and narrow-angle glaucoma. These servere eye diseases may lead to blindness. Current therapeutic approaches use carbonic anhydrase inhibitors (CA Inhibitors), beta blockers, alpha2-receptor agonists, prostaglandins and...
Supplements for T Cell-Based Immunotherapy
T Cell Activation and Prevention of Exhaustion in the treatment of cancer Optimized conceot for the activation of CAR T cells and prevention of exhaustion in the treatment of cancer.
Artificial Interferons
Interferon alpha 2 mutants with improved anti Hepatitis B virus activity The invention comprises IFNα2 mutants achieved by designing an IFNα2 with amino acids from IFNα14, which significantly improved their antiviral activity against chronic HBV. As IFNα14 is not suitable for use as a drug, unlike IFNα2, and considering that the IFNα2 mutant is almost as effective as IFNα14, it appears the...
Nano-BioTransporter
Polymer-particle light-cleavable carrier systems for photodynamic therapy (PDT) Cancer is one of the main causes of death worldwide. One of the newer therapeutic approaches is photodynamic therapy (PDT), a treatment that uses a photosensitizing chemical substance, a particular type of light and oxygen.
Polymer Wound Dressing
Effective Treatment for Chronic and Infected Wounds The treatment of chronic and infected wounds remains a major challenge in the healthcare sector. A new development by the University of Siegen and the Amsterdam University Medical Center now offers a promising solution: a therapeutic hydrogel with antimicrobial properties that combats infections.
Circular RNA
Enhanced circular RNA translation for therapeutic and immunogenic protein production Scientists of the University Hospital Bonn and Stanford University have discovered that mammalian IRES-like sequences can overcome the efficiency limitations of eukaryotic translation initiation in circular RNA therapeutics.
Further information
↗ BIO-Europe
Technology offers:
↗ All technology offers PROvendis
↗ Biotechnology
↗ Diagnostics
↗ Medical technology
↗ Pharma